Compare HNRG & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | DRTS |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Coal Mining | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.0M | 641.6M |
| IPO Year | 1995 | N/A |
| Metric | HNRG | DRTS |
|---|---|---|
| Price | $18.96 | $8.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $25.38 | $8.67 |
| AVG Volume (30 Days) | ★ 1.0M | 421.8K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.12 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $14.68 | $2.81 |
| 52 Week High | $24.70 | $9.07 |
| Indicator | HNRG | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 67.36 | 59.76 |
| Support Level | $18.89 | $6.47 |
| Resistance Level | $20.80 | $8.60 |
| Average True Range (ATR) | 1.17 | 0.63 |
| MACD | 0.46 | -0.00 |
| Stochastic Oscillator | 52.27 | 66.63 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.